SPRY earnings date and last-quarter result: next report 2026-08-12, last quarter miss, P/E -3.01. Updated 2026-07-23.
ARS Pharmaceuticals (SPRY) Research Hub
ARS Pharmaceuticals (SPRY) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 3.92 USD (-2.73%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.01, market cap 0.60B. This hub links to the full technical, earnings and options research available for SPRY.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.92 USD (-2.73%) |
| 52-week range | 3.815 USD – 10.87 USD |
| Trend regime | Range |
| 14-day RSI | 40.5 (Bearish) |
| Trailing P/E | -3.01 |
| Market cap | 0.60B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for SPRY
Covered Call on SPRY: how it works, illustrative setup around the real 3.92 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SPRY: how it works, illustrative setup around the real 3.92 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SPRY: how it works, illustrative setup around the real 3.92 USD price, max profit/loss, breakeven and when to use it. Educational.
SPRY technical analysis: range, last 3.92 USD, RSI 40.5, 52w range 3.815 USD–10.87 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is SPRY in?
ARS Pharmaceuticals (SPRY) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SPRY in an uptrend or downtrend?
As of 2026-10-26, SPRY is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SPRY's trailing P/E ratio?
SPRY's trailing P/E is -3.01, with a market cap of 0.60B. See the earnings research page for full valuation detail.
When does SPRY next report earnings?
SPRY is next scheduled to report earnings on 2026-08-12.